Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalized Peptide Vaccine in Recurrent HCC
NCT05059821Phase 1Unknown
- Start
- Apr 2021
- Primary completion
- Apr 2024
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of alpha-fetoprotein peptide + glypican-3 peptide in hepatocellular carcinoma (HCC). Primary endpoints: Assessment of the safety of the personalized cancer vaccine at 4 weeks and Assessment of immunological response at 12 weeks. Status: unknown.
02
Drugs
alpha-fetoprotein peptide + glypican-3 peptide
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05059821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05059821.